The proposed bill establishes a new section, 456.63, in the Florida Statutes, which governs stem cell therapy performed by licensed health care providers. It recognizes the potential of stem cell therapies in advancing medical treatments while emphasizing the importance of ethical standards, specifically prohibiting the use of stem cells derived from aborted fetuses. The bill defines key terms related to stem cell therapy and outlines the conditions under which health care providers may perform such therapies that are not approved by the FDA, particularly in the areas of orthopedics, wound care, and pain management. It mandates that any stem cells used must be manufactured and stored in compliance with strict FDA regulations and current good manufacturing practices.

Additionally, the bill requires health care providers to inform patients through a written notice about the unapproved status of the stem cell therapies before treatment, as well as to obtain informed consent that details the nature of the treatment, potential risks, and alternative options. The notice must be prominently displayed in the provider's office and included in any advertisements. Violations of these provisions may lead to disciplinary actions against the health care provider, and the Department of Health is tasked with adopting rules to implement the new regulations. The act is set to take effect on July 1, 2025.